Management ChangeJun 5, 2026, 12:11 PM
AbCellera Appoints Dr. Victor Sandor to Board of Directors
AI Summary
AbCellera Biologics Inc. announced the appointment of Dr. Victor Sandor to its Board of Directors as an independent director, effective June 1, 2026. Dr. Sandor brings extensive experience as a medical oncologist and in building companies, having held key leadership roles at Array BioPharma Inc. and Incyte Corporation where he contributed to the approval of several innovative medicines. He will serve until the company's next annual meeting and will be compensated under the existing non-employee director policy.
Key Highlights
- AbCellera appointed Dr. Victor Sandor as a new independent director to its Board of Directors, effective June 1, 2026.
- Dr. Sandor will serve until the next annual meeting of shareholders.
- The Board determined Dr. Sandor is independent under NASDAQ rules and company guidelines.
- He will participate in the Non-Employee Director Compensation Policy.
- Dr. Sandor previously served as Chief Medical Officer at Array BioPharma Inc. and Senior Vice President for Global Clinical Development at Incyte Corporation.
- He played critical roles in the approval of Braftovi®, Mektovi®, and Jakafi®.
- Dr. Sandor currently serves on the boards of ADC Therapeutics SA, Kymera Therapeutics Inc., and Prelude Therapeutics Incorporated.
Price Impact
More from ABCL